Istari Oncology Email Format
Biotechnology ResearchNorth Carolina, United States2-10 Employees
Istari Oncology, Inc. is a clinical-stage biotechnology company based in Durham, North Carolina, focusing on immuno-oncology and immunotherapy platforms for glioblastoma and other solid tumors. Founded in 2016 by Duke University Medical Center researchers Darell Bigner and Matthias Gromeier, the company operates with a relatively small team and emphasizes translational work aimed at advancing therapies toward clinical testing. Its efforts target brain tumors and a broader set of cancers, seeking to develop immunotherapies suitable for clinical investigation. It is positioned in the biotechnology research industry. In February 2023, Istari launched the LUMINOS-103 basket trial to evaluate lerapulturev as monotherapy, with a substudy in non-muscle-invasive bladder cancer.